LenD (Lenalidomide in CLL)
Research type
Research Study
Full title
A pilot study to establish the safety and efficacy of a combination of dexamethasone and lenalidomide in patients with relapsed or refractory chronic lymphocytic leukaemia (CLL)
IRAS ID
61635
Contact name
Amit Nathwani
Sponsor organisation
University College London
Eudract number
2010-024520-15
Clinicaltrials.gov Identifier
Research summary
Chronic lymphocytic leukaemia (CLL) is a multifaceted disease comprising complex interactions between the malignant B-lymphocytes and their microenvironment. Despite recent advances in chemo-immunotherapy, the disease remains incurable. Additionally, the majority of CLL patients are elderly and cannot tolerate more intensive therapy with combinations that include purine analogs, anthracyclines or Alemtuzumab. Patients with relapsed/refractory disease in particular have limited therapeutic options as little progress has been made with salvage regimens. Lenalidomide offers an alternative way of treating CLL because of its ability to promote tumour death, in part through modification of the tumour microenvironment. We plan to assess the safety and tolerability of the combination of dexamethasone, and continuous low dose of lenalidomide (D, LenD) in patients with relapsed or refractory CLL, who are not candidates for more intensive therapy.
REC name
London - Chelsea Research Ethics Committee
REC reference
12/LO/0051
Date of REC Opinion
27 Mar 2012
REC opinion
Further Information Favourable Opinion